Sadou Yasmine, Mésidor Miceline, Rousseau Marie-Claude
Centre Armand-Frappier Santé Biotechnologie, Institut national de la recherche scientifique (INRS), Laval, Canada.
Faculty of Pharmacy, Université de Montréal, Montréal, Canada.
Prev Med Rep. 2025 Apr 30;54:103093. doi: 10.1016/j.pmedr.2025.103093. eCollection 2025 Jun.
People living with multiple sclerosis use medications for several indications, but little is known about their prescription drug use in Quebec, notably because the public drug insurance covers only part of the population. We compared the characteristics of those with public drug insurance to those privately covered.
In a cohort of persons born in 1970-1974, we identified those living with multiple sclerosis by applying a validated algorithm to administrative health data. Individuals with public coverage were those who had at least one covered period after their date of diagnosis between January 1, 1997, and December 31, 2014. We used descriptive statistics to compare sociodemographic and healthcare utilization characteristics by type of coverage.
Among the 1363 persons living with multiple sclerosis, 720 (53 %) were covered by the public drug insurance. Individuals with public drug coverage were younger, more likely to be materially and socially deprived, and had a lower median income than those with private insurance, but otherwise had similar sociodemographic characteristics. The proportion of people who had at least one multiple sclerosis-related visit to a general practitioner (39 % versus 45 %) and hospitalization (6 % versus 3 %) differed among those with public compared to private coverage. However, the utilization of other health services, including neurologist consultations, did not differ by type of drug coverage.
People with multiple sclerosis covered by the public and private drug insurance differed in terms of age, income, deprivation, multiple sclerosis-related visits to a general practitioner and hospitalizations, but not neurologist consultations.
多发性硬化症患者使用多种药物治疗多种适应症,但对于他们在魁北克的处方药使用情况知之甚少,特别是因为公共药物保险仅覆盖部分人群。我们比较了拥有公共药物保险者与私人保险覆盖者的特征。
在一组1970年至1974年出生的人群中,我们通过对行政健康数据应用经过验证的算法来识别多发性硬化症患者。有公共保险覆盖的个体是指在1997年1月1日至2014年12月31日诊断日期之后至少有一个保险覆盖期的人。我们使用描述性统计方法按保险类型比较社会人口统计学和医疗保健利用特征。
在1363名多发性硬化症患者中,720人(53%)有公共药物保险覆盖。有公共药物保险的个体更年轻,在物质和社会方面更易处于不利地位,且收入中位数低于有私人保险的个体,但在其他社会人口统计学特征方面相似。与私人保险覆盖者相比,有公共保险覆盖者中至少有一次因多发性硬化症就诊于全科医生的比例(39%对45%)和住院比例(6%对3%)有所不同。然而,包括神经科医生会诊在内的其他医疗服务利用情况在药物保险类型之间没有差异。
公共和私人药物保险覆盖的多发性硬化症患者在年龄、收入、不利状况、因多发性硬化症就诊于全科医生和住院情况方面存在差异,但在神经科医生会诊方面没有差异。